11 results about "Upper digestive tract" patented technology

The invention belongs to the field of microorganisms and medicine health care, and relates to an ackermania muciniphila strain and application thereof, the preservation number of the ackermania muciniphila strain is CGMCC (China General Microbiological Culture Collection Center) No.34370, and a 16SrDNA (Deoxyribose Nucleic Acid) sequence of the ackermania muciniphila strain has 93% similarity with a sequence shown as SEQ ID NO: 1. The new ackermania muciniphila strain (AKKBC300) is separated from a healthy human body and has good safety; good tolerance to low pH value and bile salt is shown in vitro, and it is indicated that the compound can reach the intestinal tract through the upper digestive tract and play a role; according to the present invention, genomics analysis results prove that the bacterial strain contains the gene Akkermansia BC00573 with high homology with the known probiotic functional protein Amuc1100, such that the molecular basis is provided;

This invention relates to a device for electric field therapy of the human digestive tract, comprising: an inner guide rod, an outer sleeve, a rotating ring, and a supporting component, with an electrode array membrane spirally wound around the supporting component. When the supporting component is in a radially contracted state, the invention can be placed within the surgical instrument channel of a commonly used gastroscopy. When the supporting component is in a radially expanded state, it supports the electrode array membrane, enabling accurate electric field therapy of the upper digestive tract, particularly the inner wall of the duodenum.

The present application relates to a kind of electric field treatment device for digestive tract, it includes: slender rod, sleeve, expandable component, the expandable component includes: multiple groups of support framework, multiple groups of electrode array film;When the sleeve is slid forward to first position relative to the slender rod, the expandable component is in first expansion working state;When the sleeve is slid forward again to second position relative to the slender rod, the expandable component is in second expansion working state;The present application can accurately carry out electric field treatment to the inner wall of upper digestive tract, especially duodenum.

The invention discloses a colon-targeted slow-release PLA-Eudragit S100 nanofiber membrane as well as a preparation method and application thereof, and belongs to the technical field of nano medical materials. The nanofiber membrane comprises a pharmaceutical active component and a fiber matrix, wherein the pharmaceutical active component is dispersed in the fiber matrix formed by blending PLA (Polylactic Acid) and Eudragit S100; the nanofiber membrane has colon pH environment response, and multistage pore channels are formed through corrosion of the fiber matrix in a colon pH environment. Unique pore channels in the nanofiber membrane form a synergistic mechanism with skeleton slow release, precise control of the medicine from intelligent triggering to programmed slow release is achieved, the stability of the medicine in the upper digestive tract can be effectively protected, the local concentration and bioavailability of the medicine in the colon part are remarkably improved, the preparation process is simple, and large-scale production is easy.

Tubular prostheses are provided for use in the airways, upper digestive tract, and urinary tract. Each of these uses has its own set of biological specifications, based on what it must contain and discharge, as well as the physical and chemical pressures and loads to which it is subjected. The prostheses can be fabricated from allogeneic cells. Therefore, they can be fabricated and stored before an individual's personal need arises.

This invention relates to the fields of biomedicine and functional food technology, and discloses an intestinal immune regulation system based on the microenvironmental release of black goji berry polysaccharides (LBPs). The system includes a microenvironment-responsive delivery unit for delivering and releasing LBPs. The delivery unit comprises a LBP core and a responsive layer encapsulating the core. The responsive layer contains at least one responsive material capable of responding to microenvironmental signals at the intestinal target site, enabling the delivery unit to undergo structural changes in response to these signals upon reaching the intestinal target site, thereby achieving the targeted release of the LBPs. This intestinal immune regulation system based on the microenvironmental release of LBPs constructs a physical barrier by encapsulating the active core of LBPs with a "responsive layer" composed of responsive materials. This system can effectively resist the damage to the LBP structure caused by the harsh environment of the upper digestive tract.

The application provides a prebiotic composition based on in-vitro simulation and artificial intelligence collaborative optimization, and an optimization method and system thereof, which comprises the following steps: determining a target physiological function to be adjusted, identifying microbial functional characteristics and genera related to the target physiological function, and then deducing candidate prebiotics; constructing an in-vitro multi-chamber intestinal simulation system to simulate the physiological environment from the upper digestive tract to the colon and inoculate intestinal flora samples; establishing a machine learning model to predict the influence of different prebiotic combinations on the abundance of target genera and the activity of metabolic pathways, thereby selecting candidate prebiotic combinations; introducing the candidate prebiotic combinations predicted by the machine learning model into the simulation system, detecting changes in flora composition and metabolic product distribution, and verifying the actual effect of the candidate prebiotic combinations; based on the actual effect verified in step S4, optimizing the parameters of the machine learning model in step S3 to form a closed-loop iterative screening process.

The invention provides a preparation method of fermented polygonatum kingianum polysaccharide and polygonatum kingianum hepta-oligosaccharide, which comprises the following steps: preparing fermented polygonatum kingianum by virtue of fermentation of pediococcus ethanolidurans, extracting the fermented polygonatum kingianum polysaccharide, and extracting and purifying the fermented polygonatum kingianum polysaccharide to obtain brand-new polygonatum kingianum hepta-oligosaccharide with the structural formula of alpha-D-Glcp-1-(2-beta-D-Fruf-1) 5-2-beta-D-Fruf, the enterococcus faecium has excellent tolerance to an upper digestive tract environment, can be selectively utilized by intestinal microflora at cecum and colon parts, specifically increases relative abundance of beneficial intestinal flora, remarkably promotes proliferation of enterococcus and lactobacillus, also can reduce the pH value of colon, optimizes intestinal microecological balance, stimulates biosynthesis of short-chain fatty acid, and has a good application prospect. The prebiotic tea has an excellent prebiotic effect and a wide application prospect.

The invention is suitable for the technical field of health-care food, and provides an edible mushroom composition with an intestinal flora regulating function and a preparation method of the edible mushroom composition. The edible mushroom composition comprises grifola frondosa polysaccharide, cordyceps militaris polysaccharide, ganoderma sinensis extract, hericium erinaceus polysaccharide, agaricus blazei polysaccharide, lentinan, pleurotus nebrodensis polysaccharide, auricularia polytricha polysaccharide, agaricus bisporus polysaccharide and pachymaran, and the ratio of the materials is optimized based on the theory of monarch, minister, assistant and guide. The preparation method comprises the following steps: carrying out all-component stepped extraction on ganoderma sinensis, carrying out function-oriented graded extraction on other mushrooms, and carrying out a key gradient self-assembly process. According to the method, composite particles with time sequence release characteristics are constructed through a gradient self-assembly process, functional division of rapid release of adjuvant drugs in the upper digestive tract and slow release of monarch drugs in the intestinal tract is achieved, time sequence control of active ingredients is achieved, and the effects of regulating immunity, improving intestinal flora and improving yang deficiency symptoms are achieved.

This invention relates to the field of medical device technology, and discloses a device for collecting early gastrointestinal cancer cells, comprising a silicone-coated polyester thread; a sponge ball fixedly mounted on the surface of the silicone-coated polyester thread; and a capsule disposed outside the sponge ball for wrapping the sponge ball. One end of the silicone-coated polyester thread passes through the capsule and extends to the outside of the capsule. Compared with traditional endoscopes, this device for collecting early gastrointestinal cancer cells adopts a capsule shape, allowing the patient to complete the insertion of the collection device by swallowing the capsule, significantly reducing discomfort in the throat. The capsule contains a compressed spherical sponge ball with a diameter of 30mm, which is small in size and causes less irritation to the digestive tract, making it easier for patients to accept. Since the patient can move freely after swallowing the capsule, the collection process is not limited to a specific environment and can be performed in any environment, which increases the flexibility of collection, improves the effectiveness of the device, and meets practical needs.

The invention discloses a preparation method of mesalazine sustained-release granules and the sustained-release granules. The sustained-release granule comprises a mesalazine drug-containing granule core and a sustained-release coating layer wrapping the mesalazine drug-containing granule core, and the sustained-release coating layer is made of an azobenzene methacrylate copolymer. After oral administration, the coating layer can completely pass through the upper digestive tract and reach the colon, azo bonds in the structure of the coating layer can be specifically degraded by special azo reductase in the colon, so that the coating layer is gradually damaged to form a diffusion channel, and mesalazine can be slowly and continuously released at the colon part along with the expansion of the channel; and accurate colon targeted drug delivery is realized. According to the invention, premature release of the medicine in the stomach and the small intestine and possible burst release risk are effectively avoided, and the concentration and curative effect of the medicine in the diseased region are remarkably improved. In addition, the granule dosage is convenient for dose adjustment, the production process is simple, and the granule has a good clinical application prospect.